Literature DB >> 34016726

Determining the axillary nodal status with four current imaging modalities including 18F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.

Janna Morawitz1, Nils-Martin Bruckmann1, Frederic Dietzel1, Tim Ullrich1, Ann-Kathrin Bittner2, Oliver Hoffmann2, Svjetlana Mohrmann3, Lena Haeberle4, Marc Ingenwerth5, Lale Umutlu6, Wolfgang Peter Fendler7, Tanja Fehm8, Ken Herrmann9, Gerald Antoch1, Lino Morris Sawicki1, Julian Kirchner1.   

Abstract

Purpose: To compare breast magnetic resonance imaging (MRI), thoracal MRI, thoracal 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET)/MRI and axillary sonography for the detection of axillary lymph node metastases in women with newly diagnosed breast cancer. Materials and
Methods: This prospective double-center study included patients with newly diagnosed breast cancer between March 2018 and December 2019. Patients underwent thoracal (18F-FDG PET/)MRI, axillary sonography, and dedicated prone breast MRI. Datasets were evaluated separately regarding nodal status (nodal+ vs. nodal-). Histopathology served as reference standard in all patients. The diagnostic performance of breast MRI, thoracal MRI, thoracal PET/MRI and axillary sonography in detecting nodal positive patients was tested by creating receiver-operating-characteristic curves (ROC) with a calculated area under the curve (AUC). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for all four modalities. A McNemar test was used to assess differences.
Results: 112 female patients (mean age 53.04 ± 12.6 years) were evaluated. Thoracal PET/MRI showed the highest ROC-AUC with a value of 0.892. The AUC for breast MRI, thoracal MRI and sonography were 0.782, 0.814 and 0.834, respectively. Differences between thoracal PET/MRI and axillary sonography, thoracal MRI and breast MRI were statistically significant (PET/MRI vs. axillary sonography, P = 0.01; PET/MRI vs. thoracal MRI, P = 0.02; PET/MRI vs. breast MRI, P = 0.03). PET/MRI showed the highest sensitivity (81.8%, 36/44) (95%-CI: 67.29-91.81%) while axillary sonography had the highest specificity (98.5%, 65/66), 95%-CI: 91.84-99.96%).
Conclusion: 18F-FDG PET/MRI outperforms axillary sonography, breast MRI and thoracal MRI in determining the axillary lymph node status. In a clinical setting, the combination of 18F-FDG PET/MRI and axillary sonography might be considered to provide even more accuracy in diagnosis.
Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  Breast; Oncology: Breast; PET/MRI; axillary lymph node metastasis; breast cancer; oncological imaging

Year:  2021        PMID: 34016726      PMCID: PMC8612201          DOI: 10.2967/jnumed.121.262009

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  32 in total

1.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.

Authors:  Gary H Lyman; Armando E Giuliano; Mark R Somerfield; Al B Benson; Diane C Bodurka; Harold J Burstein; Alistair J Cochran; Hiram S Cody; Stephen B Edge; Sharon Galper; James A Hayman; Theodore Y Kim; Cheryl L Perkins; Donald A Podoloff; Visa Haran Sivasubramaniam; Roderick R Turner; Richard Wahl; Donald L Weaver; Antonio C Wolff; Eric P Winer
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

2.  Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study.

Authors:  Pascal A T Baltzer; Matthias Dietzel; Hartmut P Burmeister; Ramy Zoubi; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser
Journal:  AJR Am J Roentgenol       Date:  2011-05       Impact factor: 3.959

3.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

4.  The Z0011 Trial: Is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients?

Authors:  T P J Farrell; N C Adams; M Stenson; P A Carroll; M Griffin; E M Connolly; S A O'Keeffe
Journal:  Eur Radiol       Date:  2015-03-05       Impact factor: 5.315

5.  Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.

Authors:  Alessandro Neri; Daniele Marrelli; Franco Roviello; Alfonso De Stefano; Alfredo Guarnieri; Eleonora Pallucca; Enrico Pinto
Journal:  Ann Surg Oncol       Date:  2005-03-03       Impact factor: 5.344

Review 6.  Tumor-related prognostic factors for breast cancer.

Authors:  W L Donegan
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

Review 7.  Staging of breast cancer with ultrasound.

Authors:  Wei Tse Yang
Journal:  Semin Ultrasound CT MR       Date:  2011-08       Impact factor: 1.875

8.  The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review.

Authors:  V J L Kuijs; M Moossdorff; R J Schipper; R G H Beets-Tan; E M Heuts; K B M I Keymeulen; M L Smidt; M B I Lobbes
Journal:  Insights Imaging       Date:  2015-03-24

9.  Understanding and using sensitivity, specificity and predictive values.

Authors:  Rajul Parikh; Annie Mathai; Shefali Parikh; G Chandra Sekhar; Ravi Thomas
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848

10.  Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.

Authors:  Thiemo J A van Nijnatten; B Goorts; S Vöö; M de Boer; L F S Kooreman; E M Heuts; J E Wildberger; F M Mottaghy; M B I Lobbes; M L Smidt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-14       Impact factor: 9.236

View more
  1 in total

1.  Virtual Biopsy: Just an AI Software or a Medical Procedure?

Authors:  Jacob M Murray; Bodo Wiegand; Boris Hadaschik; Ken Herrmann; Jens Kleesiek
Journal:  J Nucl Med       Date:  2022-02-10       Impact factor: 10.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.